StandoutStocks.com: "Stocks that Standout" picks for today are: ADLS, EDWY, FSYS, VRTX

Jun 23, 2009 (M2 PRESSWIRE via COMTEX) -- VRTX | Quote | Chart | News | PowerRating -- StandoutStocks.com "Stocks that Standout" picks for today are: Advanced Life ciences Holdings, Inc. (OTCBB: ADLS), eDOORWAYS Corporation (PINKSHEETS: EDWY), Fuel Systems Solutions, Inc. (NASDAQ: FSYS), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)

Visit Us On Twitter and Facebook: http://twitter.com/StandoutStocks http://www.facebook.com/people/Standout-Stocks/547603354

Sign-up for our FREE Stock Alerts AND AWARD WINNING NEWSLETTER at www.Standoutstocks.com

Jun 23, 2009 -- Advanced Life Sciences Holdings, Inc. (OTCBB: ADLS), today announced that a second non-human primate study involving its novel, once-a-day, oral antibiotic Restanza(TM) (cethromycin), showed that a 14-day course of Restanza achieved a 100% survival rate against an inhaled lethal dose of anthrax. All of the animals in the study that received 16 mg/kg once-a-day (the human equivalent dose of 300 mg) of Restanza within 24 hours after exposure to anthrax survived while none of the animals that received placebo survived. The study was supported by the National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH), which is a component of the Department of Health and Human Services (HHS), an agency of the U.S. Government.

"The successful outcome of the study provides strong evidence of Restanza's life saving potential and underscores its value as a potent new biodefense countermeasure," said Dr. Michael Flavin, Chairman and CEO of Advanced Life Sciences. "When coupled with the positive outcome of the pivotal primate study that we announced in May 2007, we believe that these significant findings complete the regulatory package for Restanza in the post-exposure prophylactic treatment of inhalation anthrax indication. We are looking forward to working with NIAID on the final study report and submitting our data package for regulatory review based on our NDA for Restanza, which is currently under review by the FDA for the treatment of mild-to-moderate community acquired pneumonia (CAP)."

Restanza as a Biodefense Countermeasure

Advanced Life Sciences is developing Restanza for the post-exposure prophylactic treatment of inhalation anthrax to help protect against human infection from anthrax. In studies conducted by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Restanza was shown to be highly active in vitro against 30 strains of anthrax. In May 2007, a non-human primate study showed that a 30-day course of oral Restanza was 100% protective against a lethal dose of inhaled anthrax as compared to the standard of care, Cipro(R) (ciprofloxacin), which demonstrated 90% protection. The FDA has designated Restanza as an orphan drug for the post-exposure prophylactic treatment of inhalation anthrax, but the FDA has not yet approved the drug for marketing in this or any other indication.

In addition to its development in anthrax, Restanza is also being developed to combat other high priority bioterror agents such as Fransicella tularensis (tularemia), Yersinia pestis (plague) and Burkholderia pseudomallei (melioidosis) under a two year, $3.8 million contract with the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense.

FDA's "Animal Efficacy Rule" and the Use of Non-Human Primates

The "Animal Efficacy Rule" allows for approval of new drug products based on animal data when adequate and well-controlled efficacy studies in humans cannot be ethically conducted because the studies would involve administering a potentially lethal or permanently disabling toxic substance or organism to healthy human volunteers. Approval of a drug under the "Animal Efficacy Rule" is subject to certain post-approval commitments, including the submission of a plan for conducting post-marketing studies, post-marketing restrictions to ensure safe use (if deemed necessary), and product labeling information intended for patient advising that, among other things, indicates the product's approval was based on efficacy studies conducted in animals alone.

The non-human primates used in the study referenced above were used to help understand anthrax disease mechanisms and to assess novel approaches for the prophylactic treatment of inhalation anthrax in lieu of human efficacy testing pursuant to FDA's "Animal Efficacy Rule" (21 C.F.R. Section 314.600-650). The study referenced above was carried out in accordance with the Animal Welfare Act (AWA) under the supervision of an Institutional Animal Care and Use Committee (IACUC), which is responsible for enforcing the AWA.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases.

Jun 22, 2009 -- eDOORWAYS Corporation (PINKSHEETS: EDWY | Quote | Chart | News | PowerRating) Chairman & CEO Mr. Gary Kimmons encourages shareholder communication through the company's corporate blog indicating that it is a platform of transparency -- partly fueling shareholder confidence.

"We believe initiating the Corporate Blog was one of the best things the company could have done to foster transparency," said Kimmons. "We receive hundreds of hits daily and field dozens of comments. Good, bad or indifferent we respond to any inquiry, where appropriate or legally permissible, with a sense of responsibility and detail that shareholders deserve. As a developing company trading within the dynamics of any economy, investors need to know the facts in order to make educated decisions that result in long term investments in any company. That's what we aspire to -- achieving long term holders of eDOORWAYS stock."

Over the past eight months, eDOORWAYS has administered a communication campaign aimed at the accurate and most transparent dissemination of company information and the procurement of good company/shareholder relations. This includes shareholder letters, info packets, conference calls and a whole host of other communiques with the corporate blog seemingly the most prominent. According to people close to the company, this approach actually opened the company up to much ridicule and hard questions to answer. However, due to the company's commitment to stand behind the truth and its viability, eDOORWAYS seems to have garnered strong shareholder support.

With next week's shareholder conference call expected to announce extremely favorable information regarding this year's launch of the company's highly anticipated Web 3.0 platform, shareholders have been using the corporate blog as an open line of communication with the company. A mix of high praises and hard line questions posted to the blog seem to reflect shareholders simply seeking reaffirmation of their current positions -- increasing correspondence with the company tenfold. Blog comments have mounted from a handful of monthly posts to dozens of comments weekly. Phone calls, emails and info packet requests have also increased significantly.

"We welcome it!" stated Kimmons. "We are the 'real deal' and as such, willing to do whatever it takes to convey these simple realities to the public. eDOORWAYS will launch. The platform will begin generating revenue within the first four months of our launch. We're likely to have the second 'doorway' operating shortly after the initial launch which will positively affect our initial revenue projections."

Optimism at eDOORWAYS continues to grow as the company prepares for the June 29th conference call to announce its 2009 launch date. People close to the company expect to see blog correspondence increase as the market continues to show EDWY good favor.

Jun 23, 2009 -- Fuel Systems Solutions, Inc. (NASDAQ: FSYS | Quote | Chart | News | PowerRating) has entered into definitive purchase agreements with selected institutional investors to sell 1,500,000 shares of its common stock, par value $0.001 per share, at a price of $20.00 per share in a registered direct offering. The company expects to receive gross proceeds from the offering of approximately $30.0 million, before deducting placement agent's fees and other offering expenses. The company intends to use the net proceeds from this offering for general corporate purposes, which may include the repayment or refinancing of indebtedness or the acquisition of complementary products or businesses which further its corporate strategy. The offering is expected to close on or about June 26, 2009, subject to customary closing conditions.

The shares of common stock are being offered by the company pursuant to its existing shelf registration statement, which was filed with and declared effective by the Securities and Exchange Commission on June 18, 2009. A prospectus supplement describing the terms of the offering, which forms a part of the effective Registration Statement, will be filed with the Securities and Exchange Commission.

Needham & Company, LLC served as exclusive placement agent for the offering. The shares of common stock may be offered only by means of a prospectus. Copies of the prospectus supplement and the accompanying base prospectus relating to this offering, when available, may be obtained at the Securities and Exchange Commission's website at http://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Fuel Systems Solutions

Fuel Systems Solutions, Inc. is a leading designer, manufacturer and supplier of proven, cost-effective alternative fuel components and systems for use in transportation and industrial applications.

Fuel Systems' components and systems control the pressure and flow of gaseous alternative fuels, such as propane and natural gas, used in internal combustion engines. These components and systems feature the company's advanced fuel system technologies, which improve efficiency, enhance power output and reduce emissions by electronically sensing and regulating the proper proportion of fuel and air required by the internal combustion engine. In addition to the components and systems, the company provides engineering and systems integration services to address unique customer requirements for performance, durability and configuration.

The company is composed of two operating subsidiaries: IMPCO Technologies and BRC. IMPCO Technologies is a leader in the heavy duty, industrial, power generation and stationary engines sectors. BRC is a leader in the light duty and automobile alternative fuel sectors and has established alliances with several major automobile manufacturers for OEM projects.

Jun 23, 2009 -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX | Quote | Chart | News | PowerRating) today announced that it will webcast its corporate presentation at the 2009 Piper Jaffray Europe Conference on Tuesday, June 23, 2009 at 4:30 p.m. BST (11:30 a.m. EDT).

The presentation will be webcast live and may be accessed from 'Events & Presentations' on the home page of Vertex's website at www.vrtx.com. A replay of the webcast will also be available on the Company's website for two weeks following the presentation. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.

About Vertex

Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, cancer, and pain. Vertex co-discovered the HIV protease inhibitor, Lexiva, with GlaxoSmithKline.

Lexiva is a registered trademark of the GlaxoSmithKline group of companies.

About Standoutstocks.com

Standoutstocks.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies.

Standoutstocks.com email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Standout StocksReport home page at www.Standoutstocks.com and select the "join now" button.

Join us at www.standoutstocks.com for a complimentary subscription to the most exciting online financial newsletter on the market.

Disclaimer: Verify all claims and do your own due diligence. Standoutstocks.com profiles are not a solicitation or recommendation to buy, sell or hold securities. Standoutstocks.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Standoutstocks.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), Standoutstocks.com is owned and operated by Standoutstocks.com. Neither Standoutstocks.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Standoutstocks.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Standoutstocks.com statements and opinions and such statements and opinions cannot be considered independent. Standoutstocks.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Standoutstocks.com services are often paid for using free-trading shares. Standoutstocks.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Visit us for a full Disclaimer at: www.standoutstocks.com/disclaimer.aspx

CONTACT: Jason A. Hilton, New Media Advisors LLC Tel: +1 866 704 0122 e-mail: Jason@Newmediaadvisorsllc.com Standout Stocks.com e-mail: info@standoutstocks.com WWW: http://www.standoutstocks.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index